AstraZeneca and Joslin to use iPS cells to investigate diabetes

AstraZeneca Plc has signed a research agreement with the Joslin Diabetes Center in Boston, Massachusetts to use stem cells to generate new research tools for investigating the causes of Type 2 diabetes.